Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the ValRIETEs study and the SOME-RIETE trial.

IF 3.7 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Maria Barca-Hernando, Sonia Otalora-Valderrama, Juan Jose Lopez-Nuñez, Jose Portillo-Sanchez, Javier Pagan-Escribano, Patricia Lopez-Miguel, Isabelle Mahe, Elisabeth Mena-Muñoz, Ines Jou-Segovia, Egidio Imbalzano, Paloma Agudo-de Blas, Alicia Lorenzo-Hernandez, Carmen Diaz-Pedroche, Jesus Aibar-Gallizo, Gloria de la Red-Bellvis, Fatima Del Molino-Sanz, Cristina Amado-Fernandez, Jose Luis Fernandez-Reyes, Aurora Villalobos-Sanchez, Juan Bosco Lopez-Saez, Ana Maria Diaz-Brasero, Maria Marcos-Jubilar, Jose Meireles, Pablo Javier Marchena-Yglesias, Jose Antonio Diaz-Peromingo, Samira Marin-Romero, Teresa Elias-Hernandez, Henry A Andrade-Ruiz, Ghazaleh Mehdipour, Behnood Bikdeli, Luis Jara-Palomares
{"title":"Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the ValRIETEs study and the SOME-RIETE trial.","authors":"Maria Barca-Hernando, Sonia Otalora-Valderrama, Juan Jose Lopez-Nuñez, Jose Portillo-Sanchez, Javier Pagan-Escribano, Patricia Lopez-Miguel, Isabelle Mahe, Elisabeth Mena-Muñoz, Ines Jou-Segovia, Egidio Imbalzano, Paloma Agudo-de Blas, Alicia Lorenzo-Hernandez, Carmen Diaz-Pedroche, Jesus Aibar-Gallizo, Gloria de la Red-Bellvis, Fatima Del Molino-Sanz, Cristina Amado-Fernandez, Jose Luis Fernandez-Reyes, Aurora Villalobos-Sanchez, Juan Bosco Lopez-Saez, Ana Maria Diaz-Brasero, Maria Marcos-Jubilar, Jose Meireles, Pablo Javier Marchena-Yglesias, Jose Antonio Diaz-Peromingo, Samira Marin-Romero, Teresa Elias-Hernandez, Henry A Andrade-Ruiz, Ghazaleh Mehdipour, Behnood Bikdeli, Luis Jara-Palomares","doi":"10.1016/j.ahj.2025.02.004","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Unprovoked venous thromboembolism (VTE) is considered when no clear major provoking factor for VTE is identified. Although the 1-year risk of diagnosing new cancer in these patients can be as high as 5%, the benefits of extensive screening remain uncertain. It is possible that in a risk-enriched population of patients, screening yields benefit. Recently, the RIETE score, a composite score including sex, age, chronic pulmonary disease, anemia, platelet count and previous VTE, was found to improve risk prediction for identification of occult cancer in patients with unprovoked VTE. As for screening tests, whole body 18F-fluorodeoxyglucose Positron Emission/Computed Tomography (18F-FDG PET/CT) is a promising and sensitive tool for occult cancer screening.</p><p><strong>Design: </strong>This manuscript summarizes the rationale and design of two prospective studies in patients with unprovoked symptomatic VTE: 1) ValRIETE is an international, multicenter, prospective, adaptative, cohort study that plans to include 1,550 patients; the adaptive design permits a sample size increase depending on the results of the predefined interim analysis. This study will enable the external validation of the RIETE score, with several ancillary aims related to additional clinical and biomarker predictors. Recruitment began in December 2022. 2) SOME-RIETE is an open-label, randomized, multicenter clinical trial that plans to enroll 650 patients with a RIETE score ≥ 3 to compare limited screening with limited screening plus whole body 18F-FDG PET/CT. The primary outcome is cancer diagnosis within 3 months after VTE event. Secondary outcomes include cancer diagnosis and mortality at 12 months. This study provides clinically meaningful data on and the utility of extended screening of cancer by 18F-FDG PET/CT.</p><p><strong>Trial registration: </strong>SOME-RIETE: ClinicalTrials.gov (NCT03937583) STUDY REGISTRATION: ValRIETE study: ethics committee of the Virgen del Rocio University Hospital, Sevilla (Spain). https://www.juntadeandalucia.es/salud/portaldeetica/xhtml/inicio/inicio.iface (1687-N-22).</p>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ahj.2025.02.004","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale: Unprovoked venous thromboembolism (VTE) is considered when no clear major provoking factor for VTE is identified. Although the 1-year risk of diagnosing new cancer in these patients can be as high as 5%, the benefits of extensive screening remain uncertain. It is possible that in a risk-enriched population of patients, screening yields benefit. Recently, the RIETE score, a composite score including sex, age, chronic pulmonary disease, anemia, platelet count and previous VTE, was found to improve risk prediction for identification of occult cancer in patients with unprovoked VTE. As for screening tests, whole body 18F-fluorodeoxyglucose Positron Emission/Computed Tomography (18F-FDG PET/CT) is a promising and sensitive tool for occult cancer screening.

Design: This manuscript summarizes the rationale and design of two prospective studies in patients with unprovoked symptomatic VTE: 1) ValRIETE is an international, multicenter, prospective, adaptative, cohort study that plans to include 1,550 patients; the adaptive design permits a sample size increase depending on the results of the predefined interim analysis. This study will enable the external validation of the RIETE score, with several ancillary aims related to additional clinical and biomarker predictors. Recruitment began in December 2022. 2) SOME-RIETE is an open-label, randomized, multicenter clinical trial that plans to enroll 650 patients with a RIETE score ≥ 3 to compare limited screening with limited screening plus whole body 18F-FDG PET/CT. The primary outcome is cancer diagnosis within 3 months after VTE event. Secondary outcomes include cancer diagnosis and mortality at 12 months. This study provides clinically meaningful data on and the utility of extended screening of cancer by 18F-FDG PET/CT.

Trial registration: SOME-RIETE: ClinicalTrials.gov (NCT03937583) STUDY REGISTRATION: ValRIETE study: ethics committee of the Virgen del Rocio University Hospital, Sevilla (Spain). https://www.juntadeandalucia.es/salud/portaldeetica/xhtml/inicio/inicio.iface (1687-N-22).

求助全文
约1分钟内获得全文 求助全文
来源期刊
American heart journal
American heart journal 医学-心血管系统
CiteScore
8.20
自引率
2.10%
发文量
214
审稿时长
38 days
期刊介绍: The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信